SEC EDGARJUN 51 min read$PGNY

Livingston Mark S. sold $64K of PGNY

Livingston Mark S. (CHIEF FINANCIAL OFFICER) sold 2,517 shares of Progyny, Inc. (PGNY) at $25.50 across 2 trades on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Livingston Mark S.

Published Jun 5, 2026, 8:38 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 28, 2026, 3:54 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PGNY

Bearish

medium confidence

Mentioned

$PGNY

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PGNYBearishLow

Why it matters

Insider sales often lead to short‑term price dips, though the amount here is modest.

Market read

A small insider sell by the CFO may cause slight downward pressure on PGNY shares.

What to watch

Potential tax planning or portfolio rebalancing could be driving the sale, not company fundamentals.

Relevance 2/10Novelty 2/10Timing: pre‑market on 2026‑06‑04

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PGNYBearishMedium confidence

Context

CFO Mark Livingston sold 2,517 shares for $64,183.50 via a 10b5‑1 plan on 2026‑06‑04.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

CFO offloading a modest stake via a pre‑arranged plan suggests limited material impact but could prompt short‑term downside.

Market effects

Sector

Minimal effect on the broader HR benefits sector.

Regional

No significant regional impact.

Global

Limited to PGNY investors.

Counterpoint

What could challenge this read

The sale may be routine under a 10b5‑1 plan and not indicative of future performance.

Key entities

Company
Progyny, Inc.
Provider of fertility benefits.
Individual
Mark S. Livingston
Chief Financial Officer of Progyny.

Read at source ← All news

SEP 10

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

tradingview.com3 min

SEP 8

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

yahoo.com3 min

SEP 8

$PGNYMed

Progyny at Wells Fargo healthcare conference: growth runway stays wide

Progyny (PGNY) presented at the Wells Fargo Healthcare Conference, noting seasonal August softness but expecting a September recovery. The company serves 7.2M lives, with a large addressable market. It adjusted 2024 guidance downward but emphasized long-term growth, new product lines, and strong cash flow. Management highlighted Progyny's leading position in fertility benefits and expansion into women's health. The stock is trading below its Fair Value, with a PEG ratio of 0.46, according to Inv

investing.com2 min

AUG 28

$ELVHighAI 8/10

Health Insurance Providers Stocks Q2 In Review: Elevance Health (NYSE:ELV) Vs Peers

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. UnitedHealth (UNH) reported $112B revenue, flat YoY, also beating estimates. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, missing guidance. Molina Healthcare (MOH) reported $10.87B revenue, down 4.8% YoY, missing guidance. All stocks have declined since earnings.

yahoo.com3 min

AUG 20

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

finance.yahoo.com3 min